EGFR and non-small cell lung carcinoma: For patients with advanced non-small cell lung cancer (NSCLC) harboring sensitizing epidermal growth factor receptor (EGFR) mutations, third-generation EGFR tyrosine kinase inhibitors (TKIs) are the established standard for first-line treatment.